Due to a production error, there was a mistake in Table 1 as published. The table erroneously contained references. The corrected Table 1 appears below.
TABLE 1
| Group A | Group B | Group C | P | |
|---|---|---|---|---|
| Number of patients | 193 | 200 | 58 | |
| Sex (n, %) | ||||
| Male patients | 154 (79.79) | 146 (73.00) | 44 (75.86) | 0.285 |
| Female patients | 39 (20.21) | 54 (27.00) | 14 (24.14) | |
| Age, years (P25,P75) | 65 (54,73) | 65 (54,75) | 63.5 (49.5,76) | 0.748 |
| Underlying diseases (n) | ||||
| Tumor | 19 | 13 | 5 | |
| Diabetes | 6 | 19 | 6 | |
| CKD | 6 | 2 | 4 | |
| CHF | 0 | 3 | 1 | |
| COPD | 20 | 10 | 3 | |
| Site of infection, n (%) | ||||
| Intra-abdominal | 7 (3.63) | 10 (5) | 7 (12.1) | |
| Pneumonia | 180 (93.26) | 180 (9) | 48 (82.8) | |
| SSTI | 2 (1.04) | 4 (2) | 3 (5.2) | |
| Other | 4 (2.07) | 6 (3) | 0 | |
| ICU admission, n (%) | 48 (24.87) | 44 (22.00) | 13 (22.41) | 0.786 |
| PCT | 3.35 ± 13.07 | 4.39 ± 14.81 | 2.98 ± 6.47 | 0.972 |
| Treatmentduration, days (P25,P75) | 7 (5,10.5) | 7 (5,10) | 7 (5,11) | 0.369 |
| Daily dose | ||||
| 100 mg, n (%) | 161 (83.4) | 163 (81.5) | 52 (89.7) | 0.340 |
| 200 mg, n (%) | 32 (16.6) | 37 (18.5) | 6 (10.3) | |
| Hypofibrinogenemia | ||||
| Yes, n (%) | 75 (38.86) | 93 (46.50) | 23 (39.66) | 0.281 |
| No, n (%) | 118 (61.14) | 107 (53.50) | 35 (60.34) | |
| Bleeding events, n (%) | 19 (9.84) | 19 (9.5) | 7 (12.07) | 0.845 |
Baseline information.
Group A, tigecycline plus cefoperazone/sulbactam; Group B, tigecycline plus carbapenems; Group C, tigecycline plus β-lactam antibiotics without N-methylthio-tetrazole side chains; CKD, Chronic kidney disease; CHF, Congestive heart failure; COPD, Chronic obstructive pulmonary disease; SSTI, Skin and soft tissue infections.
The publisher apologizes for this mistake. The original version of this article has been updated.
Summary
Keywords
tigecycline, cefoperazone/sulbactam, carbapenems, β-lactam antibiotics, coagulation disorders, hypofibrinogenaemia
Citation
Frontiers Production Office (2024) Erratum: Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies. Front. Pharmacol. 15:1365927. doi: 10.3389/fphar.2024.1365927
Received
05 January 2024
Accepted
05 January 2024
Published
15 January 2024
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
15 - 2024
Updates
Copyright
© 2024 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.